Loading…
Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91
To analyse long-term outcome and clinical prognostic factors in medulloblastoma. We analysed 280 patients with medulloblastoma (3-18 years) included from 1991 to 1997 in the randomised multicentre trial HIT'91 comparing pre-('sandwich') and postradiation ('maintenance') chem...
Saved in:
| Published in: | European Journal of Cancer 2009-05, Vol.45 (7), p.1209-1217 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | 1217 |
| container_issue | 7 |
| container_start_page | 1209 |
| container_title | European Journal of Cancer |
| container_volume | 45 |
| creator | VON HOFF, Katja HINKES, Bernward GOETTE, Heiko SCHLEGEL, Paul G PIETSCH, Torsten KORTMANN, Rolf D KUEHL, Joachim RUTKOWSKI, Stefan GERBER, Nicolas U DEINLEIN, Frank MITTLER, Uwe URBAN, Christian BENESCH, Martin WARMUTH-METZ, Monika SOERENSEN, Niels ZWIENER, Isabella |
| description | To analyse long-term outcome and clinical prognostic factors in medulloblastoma.
We analysed 280 patients with medulloblastoma (3-18 years) included from 1991 to 1997 in the randomised multicentre trial HIT'91 comparing pre-('sandwich') and postradiation ('maintenance') chemotherapy (median follow-up of survivors for 10 years).
In 187 patients with complete staging, overall survival (OS) was higher after maintenance compared to sandwich treatment for M0 (10-year OS 91% and 62%, p=0.001) and M1 patients (10-year OS 70% and 34%, p=0.020). In M2/3 disease, 10-year OS was 42% and 45%. Incomplete staging, metastases, younger age and sandwich chemotherapy were independent adverse risk factors. Twelve percent of all relapses (13 of 107) occurred after more than five years, and 12 patients had secondary neoplasms.
After maintenance therapy, long-term survival was excellent in fully assessable patients with localised medulloblastoma, and favourable for M1 patients. Patients should be followed longer for late relapses and secondary tumours. |
| doi_str_mv | 10.1016/j.ejca.2009.01.015 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_67125893</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67125893</sourcerecordid><originalsourceid>FETCH-LOGICAL-p270t-783486bfdafae827174f9d6267d79bf35013f0e7b11581dc176f6ee1384d151f3</originalsourceid><addsrcrecordid>eNqFkMFu1DAQhi0EotvCC3BAvkBPWWacOLaPqAJaaSUu5bxynHHXKydeYgfUx-CNccXCFWmkOcw3_4w-xt4gbBGw_3Dc0tHZrQAwW8Ba8hnboFamAS3Fc7YBI02joTMX7DLnIwAo3cFLdoFGSNACNuzXLs0PTaFl4mktLk3E7TxyF8McnI38tKSHOeUSHPfWlbRkHmbuDiGOC838ZygHPtG4xpiGaHNJk-VlIVtofALLgZ4i8olcCT-ILzU8TSHX6bTGmkpzpetGqLdu7-6vDb5iL7yNmV6f-xX79vnT_c1ts_v65e7m4645CQWlUbrtdD_40XpLWihUnTdjL3o1KjP4VgK2HkgNiFLj6FD1vifCVncjSvTtFXv_J7f-932lXPb1L0cx2pnSmve9QiG1af8LVv-q7Tqo4NszuA7Vyf60hMkuj_u_tivw7gzYXOX6asOF_I8TKEFK2bW_Afwjkeg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20073440</pqid></control><display><type>article</type><title>Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91</title><source>ScienceDirect Journals</source><creator>VON HOFF, Katja ; HINKES, Bernward ; GOETTE, Heiko ; SCHLEGEL, Paul G ; PIETSCH, Torsten ; KORTMANN, Rolf D ; KUEHL, Joachim ; RUTKOWSKI, Stefan ; GERBER, Nicolas U ; DEINLEIN, Frank ; MITTLER, Uwe ; URBAN, Christian ; BENESCH, Martin ; WARMUTH-METZ, Monika ; SOERENSEN, Niels ; ZWIENER, Isabella</creator><creatorcontrib>VON HOFF, Katja ; HINKES, Bernward ; GOETTE, Heiko ; SCHLEGEL, Paul G ; PIETSCH, Torsten ; KORTMANN, Rolf D ; KUEHL, Joachim ; RUTKOWSKI, Stefan ; GERBER, Nicolas U ; DEINLEIN, Frank ; MITTLER, Uwe ; URBAN, Christian ; BENESCH, Martin ; WARMUTH-METZ, Monika ; SOERENSEN, Niels ; ZWIENER, Isabella</creatorcontrib><description>To analyse long-term outcome and clinical prognostic factors in medulloblastoma.
We analysed 280 patients with medulloblastoma (3-18 years) included from 1991 to 1997 in the randomised multicentre trial HIT'91 comparing pre-('sandwich') and postradiation ('maintenance') chemotherapy (median follow-up of survivors for 10 years).
In 187 patients with complete staging, overall survival (OS) was higher after maintenance compared to sandwich treatment for M0 (10-year OS 91% and 62%, p=0.001) and M1 patients (10-year OS 70% and 34%, p=0.020). In M2/3 disease, 10-year OS was 42% and 45%. Incomplete staging, metastases, younger age and sandwich chemotherapy were independent adverse risk factors. Twelve percent of all relapses (13 of 107) occurred after more than five years, and 12 patients had secondary neoplasms.
After maintenance therapy, long-term survival was excellent in fully assessable patients with localised medulloblastoma, and favourable for M1 patients. Patients should be followed longer for late relapses and secondary tumours.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>EISSN: 1359-6349</identifier><identifier>DOI: 10.1016/j.ejca.2009.01.015</identifier><identifier>PMID: 19250820</identifier><language>eng</language><publisher>Kidlington: Elsevier</publisher><subject>Adolescent ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Cerebellar Neoplasms - drug therapy ; Cerebellar Neoplasms - radiotherapy ; Cerebellar Neoplasms - surgery ; Child ; Child, Preschool ; Combined Modality Therapy ; Drug Administration Schedule ; Female ; Follow-Up Studies ; Humans ; Male ; Medical sciences ; Medulloblastoma - drug therapy ; Medulloblastoma - radiotherapy ; Medulloblastoma - surgery ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Neoplasm, Residual ; Neoplasms, Second Primary ; Pharmacology. Drug treatments ; Proportional Hazards Models ; Survival Rate ; Treatment Outcome ; Tumors ; Vincristine - therapeutic use</subject><ispartof>European Journal of Cancer, 2009-05, Vol.45 (7), p.1209-1217</ispartof><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21505554$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19250820$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>VON HOFF, Katja</creatorcontrib><creatorcontrib>HINKES, Bernward</creatorcontrib><creatorcontrib>GOETTE, Heiko</creatorcontrib><creatorcontrib>SCHLEGEL, Paul G</creatorcontrib><creatorcontrib>PIETSCH, Torsten</creatorcontrib><creatorcontrib>KORTMANN, Rolf D</creatorcontrib><creatorcontrib>KUEHL, Joachim</creatorcontrib><creatorcontrib>RUTKOWSKI, Stefan</creatorcontrib><creatorcontrib>GERBER, Nicolas U</creatorcontrib><creatorcontrib>DEINLEIN, Frank</creatorcontrib><creatorcontrib>MITTLER, Uwe</creatorcontrib><creatorcontrib>URBAN, Christian</creatorcontrib><creatorcontrib>BENESCH, Martin</creatorcontrib><creatorcontrib>WARMUTH-METZ, Monika</creatorcontrib><creatorcontrib>SOERENSEN, Niels</creatorcontrib><creatorcontrib>ZWIENER, Isabella</creatorcontrib><title>Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91</title><title>European Journal of Cancer</title><addtitle>Eur J Cancer</addtitle><description>To analyse long-term outcome and clinical prognostic factors in medulloblastoma.
We analysed 280 patients with medulloblastoma (3-18 years) included from 1991 to 1997 in the randomised multicentre trial HIT'91 comparing pre-('sandwich') and postradiation ('maintenance') chemotherapy (median follow-up of survivors for 10 years).
In 187 patients with complete staging, overall survival (OS) was higher after maintenance compared to sandwich treatment for M0 (10-year OS 91% and 62%, p=0.001) and M1 patients (10-year OS 70% and 34%, p=0.020). In M2/3 disease, 10-year OS was 42% and 45%. Incomplete staging, metastases, younger age and sandwich chemotherapy were independent adverse risk factors. Twelve percent of all relapses (13 of 107) occurred after more than five years, and 12 patients had secondary neoplasms.
After maintenance therapy, long-term survival was excellent in fully assessable patients with localised medulloblastoma, and favourable for M1 patients. Patients should be followed longer for late relapses and secondary tumours.</description><subject>Adolescent</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cerebellar Neoplasms - drug therapy</subject><subject>Cerebellar Neoplasms - radiotherapy</subject><subject>Cerebellar Neoplasms - surgery</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Combined Modality Therapy</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medulloblastoma - drug therapy</subject><subject>Medulloblastoma - radiotherapy</subject><subject>Medulloblastoma - surgery</subject><subject>Neoplasm Recurrence, Local</subject><subject>Neoplasm Staging</subject><subject>Neoplasm, Residual</subject><subject>Neoplasms, Second Primary</subject><subject>Pharmacology. Drug treatments</subject><subject>Proportional Hazards Models</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Vincristine - therapeutic use</subject><issn>0959-8049</issn><issn>1879-0852</issn><issn>1359-6349</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNqFkMFu1DAQhi0EotvCC3BAvkBPWWacOLaPqAJaaSUu5bxynHHXKydeYgfUx-CNccXCFWmkOcw3_4w-xt4gbBGw_3Dc0tHZrQAwW8Ba8hnboFamAS3Fc7YBI02joTMX7DLnIwAo3cFLdoFGSNACNuzXLs0PTaFl4mktLk3E7TxyF8McnI38tKSHOeUSHPfWlbRkHmbuDiGOC838ZygHPtG4xpiGaHNJk-VlIVtofALLgZ4i8olcCT-ILzU8TSHX6bTGmkpzpetGqLdu7-6vDb5iL7yNmV6f-xX79vnT_c1ts_v65e7m4645CQWlUbrtdD_40XpLWihUnTdjL3o1KjP4VgK2HkgNiFLj6FD1vifCVncjSvTtFXv_J7f-932lXPb1L0cx2pnSmve9QiG1af8LVv-q7Tqo4NszuA7Vyf60hMkuj_u_tivw7gzYXOX6asOF_I8TKEFK2bW_Afwjkeg</recordid><startdate>20090501</startdate><enddate>20090501</enddate><creator>VON HOFF, Katja</creator><creator>HINKES, Bernward</creator><creator>GOETTE, Heiko</creator><creator>SCHLEGEL, Paul G</creator><creator>PIETSCH, Torsten</creator><creator>KORTMANN, Rolf D</creator><creator>KUEHL, Joachim</creator><creator>RUTKOWSKI, Stefan</creator><creator>GERBER, Nicolas U</creator><creator>DEINLEIN, Frank</creator><creator>MITTLER, Uwe</creator><creator>URBAN, Christian</creator><creator>BENESCH, Martin</creator><creator>WARMUTH-METZ, Monika</creator><creator>SOERENSEN, Niels</creator><creator>ZWIENER, Isabella</creator><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>20090501</creationdate><title>Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91</title><author>VON HOFF, Katja ; HINKES, Bernward ; GOETTE, Heiko ; SCHLEGEL, Paul G ; PIETSCH, Torsten ; KORTMANN, Rolf D ; KUEHL, Joachim ; RUTKOWSKI, Stefan ; GERBER, Nicolas U ; DEINLEIN, Frank ; MITTLER, Uwe ; URBAN, Christian ; BENESCH, Martin ; WARMUTH-METZ, Monika ; SOERENSEN, Niels ; ZWIENER, Isabella</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p270t-783486bfdafae827174f9d6267d79bf35013f0e7b11581dc176f6ee1384d151f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adolescent</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cerebellar Neoplasms - drug therapy</topic><topic>Cerebellar Neoplasms - radiotherapy</topic><topic>Cerebellar Neoplasms - surgery</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Combined Modality Therapy</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medulloblastoma - drug therapy</topic><topic>Medulloblastoma - radiotherapy</topic><topic>Medulloblastoma - surgery</topic><topic>Neoplasm Recurrence, Local</topic><topic>Neoplasm Staging</topic><topic>Neoplasm, Residual</topic><topic>Neoplasms, Second Primary</topic><topic>Pharmacology. Drug treatments</topic><topic>Proportional Hazards Models</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Vincristine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>VON HOFF, Katja</creatorcontrib><creatorcontrib>HINKES, Bernward</creatorcontrib><creatorcontrib>GOETTE, Heiko</creatorcontrib><creatorcontrib>SCHLEGEL, Paul G</creatorcontrib><creatorcontrib>PIETSCH, Torsten</creatorcontrib><creatorcontrib>KORTMANN, Rolf D</creatorcontrib><creatorcontrib>KUEHL, Joachim</creatorcontrib><creatorcontrib>RUTKOWSKI, Stefan</creatorcontrib><creatorcontrib>GERBER, Nicolas U</creatorcontrib><creatorcontrib>DEINLEIN, Frank</creatorcontrib><creatorcontrib>MITTLER, Uwe</creatorcontrib><creatorcontrib>URBAN, Christian</creatorcontrib><creatorcontrib>BENESCH, Martin</creatorcontrib><creatorcontrib>WARMUTH-METZ, Monika</creatorcontrib><creatorcontrib>SOERENSEN, Niels</creatorcontrib><creatorcontrib>ZWIENER, Isabella</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>European Journal of Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>VON HOFF, Katja</au><au>HINKES, Bernward</au><au>GOETTE, Heiko</au><au>SCHLEGEL, Paul G</au><au>PIETSCH, Torsten</au><au>KORTMANN, Rolf D</au><au>KUEHL, Joachim</au><au>RUTKOWSKI, Stefan</au><au>GERBER, Nicolas U</au><au>DEINLEIN, Frank</au><au>MITTLER, Uwe</au><au>URBAN, Christian</au><au>BENESCH, Martin</au><au>WARMUTH-METZ, Monika</au><au>SOERENSEN, Niels</au><au>ZWIENER, Isabella</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91</atitle><jtitle>European Journal of Cancer</jtitle><addtitle>Eur J Cancer</addtitle><date>2009-05-01</date><risdate>2009</risdate><volume>45</volume><issue>7</issue><spage>1209</spage><epage>1217</epage><pages>1209-1217</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><eissn>1359-6349</eissn><abstract>To analyse long-term outcome and clinical prognostic factors in medulloblastoma.
We analysed 280 patients with medulloblastoma (3-18 years) included from 1991 to 1997 in the randomised multicentre trial HIT'91 comparing pre-('sandwich') and postradiation ('maintenance') chemotherapy (median follow-up of survivors for 10 years).
In 187 patients with complete staging, overall survival (OS) was higher after maintenance compared to sandwich treatment for M0 (10-year OS 91% and 62%, p=0.001) and M1 patients (10-year OS 70% and 34%, p=0.020). In M2/3 disease, 10-year OS was 42% and 45%. Incomplete staging, metastases, younger age and sandwich chemotherapy were independent adverse risk factors. Twelve percent of all relapses (13 of 107) occurred after more than five years, and 12 patients had secondary neoplasms.
After maintenance therapy, long-term survival was excellent in fully assessable patients with localised medulloblastoma, and favourable for M1 patients. Patients should be followed longer for late relapses and secondary tumours.</abstract><cop>Kidlington</cop><pub>Elsevier</pub><pmid>19250820</pmid><doi>10.1016/j.ejca.2009.01.015</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8049 |
| ispartof | European Journal of Cancer, 2009-05, Vol.45 (7), p.1209-1217 |
| issn | 0959-8049 1879-0852 1359-6349 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67125893 |
| source | ScienceDirect Journals |
| subjects | Adolescent Antineoplastic Agents - therapeutic use Biological and medical sciences Cerebellar Neoplasms - drug therapy Cerebellar Neoplasms - radiotherapy Cerebellar Neoplasms - surgery Child Child, Preschool Combined Modality Therapy Drug Administration Schedule Female Follow-Up Studies Humans Male Medical sciences Medulloblastoma - drug therapy Medulloblastoma - radiotherapy Medulloblastoma - surgery Neoplasm Recurrence, Local Neoplasm Staging Neoplasm, Residual Neoplasms, Second Primary Pharmacology. Drug treatments Proportional Hazards Models Survival Rate Treatment Outcome Tumors Vincristine - therapeutic use |
| title | Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91 |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T06%3A43%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20outcome%20and%20clinical%20prognostic%20factors%20in%20children%20with%20medulloblastoma%20treated%20in%20the%20prospective%20randomised%20multicentre%20trial%20HIT'91&rft.jtitle=European%20Journal%20of%20Cancer&rft.au=VON%20HOFF,%20Katja&rft.date=2009-05-01&rft.volume=45&rft.issue=7&rft.spage=1209&rft.epage=1217&rft.pages=1209-1217&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2009.01.015&rft_dat=%3Cproquest_pubme%3E67125893%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p270t-783486bfdafae827174f9d6267d79bf35013f0e7b11581dc176f6ee1384d151f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=20073440&rft_id=info:pmid/19250820&rfr_iscdi=true |